GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Price-to-Funds-From-Operations

RDHL (Redhill Biopharma) Price-to-Funds-From-Operations : (As of Dec. 12, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Redhill Biopharma Business Description

Traded in Other Exchanges
N/A
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.